Rituximab Can Be Added to Tacrolimus to Achieve a Steroid-Free Regimen
Yes, rituximab can be added to tacrolimus to achieve complete steroid-sparing in this patient, particularly if she has lupus nephritis or a steroid-dependent podocytopathy. This approach is supported by both guideline recommendations and emerging clinical evidence.
Guideline Support for Rituximab as Steroid-Sparing Agent
The 2019 EULAR guidelines explicitly state that rituximab can be considered in organ-threatening disease refractory to or with intolerance/contraindications to standard immunosuppressive agents 1. While this recommendation was written for refractory disease, the principle of using rituximab to minimize glucocorticoid exposure aligns with the overarching EULAR recommendation that "for chronic maintenance treatment, GC should be minimized to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn" 1.
For lupus nephritis specifically, the 2024 KDIGO guidelines emphasize that triple immunosuppression with glucocorticoids, tacrolimus, and low-dose mycophenolate resulted in higher complete remission rates compared to conventional therapy 2. While rituximab is mentioned as an option with 40-60% response rates in Class V lupus nephritis, the guidelines note it as one of several agents that can be combined with glucocorticoids 2.
Clinical Evidence for Rituximab Plus Tacrolimus Without Steroids
The most compelling evidence comes from recent case reports and series:
A 2025 case report demonstrated complete remission in relapsed primary FSGS using rituximab plus tacrolimus with only low-dose prednisolone (not high-dose), achieving rapid clinical improvement 3. This directly addresses your question about steroid-sparing.
A 2024 retrospective series of 14 adults with steroid-dependent podocytopathies showed that rituximab induction therapy resulted in 10/14 patients achieving complete remission at mean follow-up of 47 months 4. Critically, the number of patients requiring corticosteroids dropped from 14/14 (100%) at baseline to 7/12 (58.3%) at last follow-up, with prednisolone dose reduced from 20 mg/day to 5.25 mg/day 4.
A 2024 case report specifically described successful treatment of proliferative glomerulonephritis using rituximab combined with steroid and tacrolimus, demonstrating this triple-agent approach can work 5.
Practical Implementation Algorithm
If your patient has steroid-dependent disease (lupus nephritis or podocytopathy):
- Initiate rituximab: Standard induction is 1000 mg IV × 2 doses given 2 weeks apart 4
- Continue tacrolimus at current therapeutic dose
- Use minimal steroid coverage: Low-dose prednisolone (5-10 mg/day) or even attempt complete withdrawal after rituximab loading
- Monitor for infusion reactions: Premedicate with methylprednisolone 100 mg IV, antihistamine, and acetaminophen 30 minutes before each rituximab infusion 6
- Consider maintenance rituximab: If initial response is good, maintenance dosing (1 gram every 6 months) has shown sustained remission 4
Critical Safety Considerations
Before proceeding, you must screen for hepatitis B (HBsAg and anti-HBc) as rituximab can cause fatal HBV reactivation 6. The FDA label is explicit that HBV reactivation has been reported up to 24 months following rituximab completion 6.
Monitor for:
- Infusion reactions (most common during first infusion, onset 30-120 minutes) 6
- Severe mucocutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) 6
- Infections (consider PCP prophylaxis during treatment and for ≥6 months after) 6
- B-cell depletion and immunoglobulin levels 4
Evidence Quality and Caveats
The evidence for rituximab as a steroid-sparing agent in combination with tacrolimus is moderate quality, derived primarily from case series and retrospective studies rather than randomized trials. The 2024 retrospective series 4 and 2025 case report 3 represent the most recent and directly applicable evidence for your specific question.
Important limitation: Most rituximab efficacy data comes from steroid-dependent or frequently relapsing disease. If your patient has steroid-resistant disease, rituximab benefit may be limited 7.
The 2011 LoVAS trial data 8 showed that reduced-dose glucocorticoids plus rituximab in ANCA vasculitis allowed 89.7% of patients to discontinue prednisolone entirely, with fewer serious adverse events than high-dose steroids. While this is a different disease, it demonstrates the principle that rituximab can successfully spare steroids when combined with other immunosuppression.
Bottom line: Add rituximab to her tacrolimus regimen with the goal of maintaining steroid-free remission, using only minimal steroid coverage for rituximab infusions themselves.